Two key areas hospitals are planning major tech investments in the immediate future

http://www.healthcarefinancenews.com/news/two-key-areas-hospitals-are-planning-major-tech-investments-immediate-future?mkt_tok=eyJpIjoiTkRsaU5HTTJNVEV5WldaaSIsInQiOiJFSTVVaHdzRmdQTGVCSXZORmhReEkrbVVWNjZOdzhlOWRuRUwxeUVXNktOa2FyNVpQWkc1dXk5SGNTQjc0YndcL3BuUTkrV2xkWEVLd01qWnd2UGNrWTBFTFFzRWxWaGM3bVFOclwvYjNlbXBPSjA2d1prU0tyMmNpQ0Qwdlg4TGhUIn0%3D

 

Providers are ramping up to focus on urgent care centers and population health initiatives.

Hospitals are gearing up to spend more on population health and urgent care centers in the coming years, according to new research from two different firms.

The market for population health technologies is expected to reach $69 billion by 2025 while the urgent care center space is forecasted to grow by roughly $8 billion in 2018 to $25.93 billion by 2023.

The global population health management market was worth $118.5 million in 2016 and is slated to grow at a CAGR of roughly 16 percent from 2017 to 2025, with the rise in demand for innovative technologies and adoption of healthcare IT tools fueling the growth, Transparency Market Research said in a new report.

In terms of end-users, it’s the healthcare provider segment of the market that is expected to account for the largest share of the global market thanks to rising use of PHM tools. Insurers, pharma and “others” follow in terms of segments.

The benefits of PHM tools like data integration, data analysis, care coordination, and lowering care costs have driven an increase in their adoption, especially in the case of chronic diseases like diabetes and cardiovascular diseases which require identifying high-risk patients and disease management measures.

“This is one of the factors projected to drive the global population health management market during the forecast period,” the report authors wrote. “Developed healthcare IT infrastructure and increase in healthcare IT spending are the other factors anticipated to propel the global market during the forecast period.”

Geographically, North America and Europe are expected to dominate the market thanks to the Affordable Care Act and a rise in healthcare IT spending, owing largely to providers.

“Well-established healthcare infrastructure and strong support from public and private sectors in terms of reimbursement are attributed to the largest market share of North America,” the firm said. “A rise in awareness about population health and government initiatives such as the Affordable Care Act are anticipated to drive the market during the forecast period.”

Urgent Care Centers, meanwhile, will represent a $26 billion market by 2023, and in this year will reach just over $20 billion, ReportsnReports projected. Health systems and corporations with a stake in the healthcare industry know the model is flourishing thanks to affordable pricing, shorter wait times, an increasing elderly population, and the market is seeing more investment activity as well as strategic development partnerships between urgent care providers and hospitals. Corporate-owned urgent care centers, however, are expected to occupy the largest share of this market in 2018.

Concentra, MedExpress, American Family Care, NextCare Holdings, and FastMed Urgent Care are already major market players with CareNow Urgent Care, GoHealth Urgent Care starting to gain more of a presence as well in the United States.

Health systems looking to diversify their portfolios might do well to look at both urgent care centers and population health programs when considering how to expand their footprints. With a reputation for faster service and better pricing, both things that the rising millennial population smile at, they could be a beacon for both primary and specialty care for younger consumers as opposed to traditional practices. Additionally, with the high-deductible health plans, reasonably priced care will be especially attractive to patients who will bear a greater portion of the financial responsibility related to their care.

As these facilities grow in popularity, including them could boost not only your reputation but also your bottom line.

 

Sema4, a Mount Sinai spinout, launches with a focus on genomics

Sema4, a Mount Sinai spinout, launches with a focus on genomics

dna, genomics

New York City, New York-based Mount Sinai Health System has launched a new spinout company: Sema4.

The for-profit startup has been created from numerous parts of Mount Sinai’s Department of Genetics and Genomic Sciences and the Icahn Institute for Genomics and Multiscale Biology.

Pronounced “semaphore,” the company will utilize genomic and clinical data to transform overall clinical diagnostics. By combining everything from predictive modeling to open access data, it aims to be able to better treat and diagnose diseases.

Sema4 will be run by Eric Schadt, the chair of the Department of Genetics and Genomic Sciences and the founding director of the Icahn Institute for Genomics and Multiscale Biology.

Schadt initially came to Mount Sinai about five years ago and has since helped grow its footprint in big data and genomics. But the current landscape presented an opportune time to create Sema4.

As genomic testing becomes more complex, Schadt explained, it came down to a few questions for Mount Sinai: “How do we scale all of this? How do we aggregate and manage really large scales of data and compute on it? The decision was that it’s better done as an independent company still in partnership with Sinai,” he told MedCity in a phone interview.

Mount Sinai and Sema4 will continue to be heavily involved with each other. Sema4 is the provider of all genetic testing services for Mount Sinai. And Mount Sinai will play a key role in technology development, data mining and data integration for Sema4.

“We’ll have a very, very intimate relationship,” Schadt said. “But now we are an independent, for-profit company that is presently wholly owned by Mount Sinai.”

Mount Sinai has made a large investment in Sema4 and is currently the company’s sole investor. Over the next 12 to 18 months, the startup will use those funds to grow its business, particularly its sales and marketing teams.

But after time, Sema4 will begin raising additional capital to boost the genetic testing and data sciences portions of its business.

“Once we’re stood up as a company and have our footing that way, we’ll be in a better position to more aggressively pursue the information side, and that’ll take an even bigger investment,” Schadt said.

He did not share any specific numbers with MedCity about how much Sema4 will be looking to raise.

Currently, reproductive health is a major focus area for the startup. But moving forward, Schadt said Sema4 wants to increase its involvement in the oncology space. Additionally, the company has set its sights on using digital health tools to better engage patients.

Prior to Sema4, Mount Sinai’s AppLab and Mount Sinai Innovation Partners launched a startup called Responsive Health for app distribution platform RxUniverse.